Thomas Schall, President & CEO, Director at ChemoCentryx, holds 2.90K shares in Immuneering (Ticker: IMRX), holds 0.00 shares in ChemoCentryx (Ticker: CCXI). Most recently, Thomas Schall Bought ― shares of Immuneering on Mar 25, 2024 for an estimated value of 7.37K.